Related Experiment Videos
Brachytherapy for clinically localized prostate cancer.
1Urology, Northwest Prostate Institute, Northwest Hospital, Seattle, Washington 98133, USA.
Seminars in Surgical Oncology
|January 5, 2000
Summary
Prostate brachytherapy using Iodine-125 offers effective long-term cancer control for localized prostate cancer. This treatment shows comparable or superior outcomes to surgery and external beam radiation, with excellent disease-free survival rates.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Prostate brachytherapy is a recognized treatment for localized prostate carcinoma.
- Long-term follow-up data demonstrates its efficacy compared to other treatment modalities.
- Established techniques and outcomes are crucial for patient and physician guidance.
Purpose of the Study:
- To evaluate the long-term outcomes of Iodine-125 prostate brachytherapy.
- To compare brachytherapy results with radical prostatectomy and external-beam radiation therapy.
- To present up-to-date implant techniques and historical review of the procedure.
Main Methods:
- A cohort of 152 patients with Stage T1-T3 prostate cancer received Iodine-125 brachytherapy between 1987 and 1988.
- Patients had a median age of 70 years and varying Gleason grades.
- Disease-free survival was assessed at 5 and 10 years post-treatment via PSA levels, clinical exams, and biopsies.
Main Results:
- 5- and 10-year follow-up showed prostate-specific antigen (PSA) levels comparable to radical prostatectomy series.
- Brachytherapy outcomes were superior to several published external-beam radiation series.
- Treatment failure was defined by PSA elevation (>0.5 ng/ml), positive biopsy, or positive bone scan.
Conclusions:
- Iodine-125 prostate brachytherapy is an effective treatment for organ-confined prostate cancer.
- Long-term results support brachytherapy's role in managing localized prostate carcinoma.
- The study highlights the importance of ongoing follow-up and advanced implant techniques.